F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

The New York Times – Business:

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

Author: RSS Feed

This post first appeared in The New York Times – Business. Read the original article.